{'fraction_non_alphanumeric': 0.03688029020556227, 'fraction_numerical': 0.022974607013301087, 'mean_word_length': 4.827464788732394, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Tumours of the parotid gland--results of their treatment and some peculiarities (author's transl)].

148 cases of parotid gland tumours which had been treated during the last 15 years were analysed histomorphologically: There was found in 54.1% mixed tumour (pleomorphic adenoma), 11.5% epithelial malignant tumour, 4.1% sarcoma, 7.4% primary metastasis, 22.9% other benignant tumours. In 2.5% of 80 cases of mixed tumour a malignant degeneration was revealed. Some cases of double tumours and more seldom tumours as for instance lymphoepithelioma and malignant papillary cystadenoma are presented. A critical appraisal of primary sarcomas is following, but also a comment to the problem of primary metastasis in the parotid gland. The author's opinion is now: favourable therapeutic results can be reached in cases of small and modestly enlarged mixed tumours by means of the so-called "extracapsular" or "extended extracapsular" removal on the understanding that a critical casuistic choice was made and a skilled surgical procedure was applied. On this way relapses have been observed in 2.6% of the author's cases till now. A five years survival time of epithelial malignant tumours was found in 17.7% (88.2% of all epithelial malignant tumours had been treated at stage III and IV). All patients suffering from a sarcoma died within a period of 1/2 to 3 1/2 years after therapy except a case of Hodgkin's sarcoma (8 1/2 years). Primary metastasis in the parotid gland in cases of malignant tumours of head and skull sometimes was discovered in the author's cases, the infavourable prognosis of which was similar to primary malignant tumours at all.